Follow-up of Intensive Glucose Control in Type 2 Diabetes

Petrie, J.R. (2009) Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 360(4), pp. 416-417.

Full text not currently available from Enlighten.

Publisher's URL: http://www.nejm.org/doi/full/10.1056/NEJMc082275

Abstract

In the original UKPDS trial, when metformin was prescribed for patients who were already receiving a sulfonylurea, there was a significant increase in the risk of diabetes-related death and death from any cause. These results were attributed to a small number of end points, and they were in contrast to the positive results associated with metformin monotherapy, which have, of course, been highly influential in shaping modern clinical practice. The new data in the 10-year post-randomization follow-up show positive results associated with metformin in general, but no separate information has so far been provided regarding the subgroup of patients receiving combination therapy. Given the additional accumulation of end points, can the authors provide reassurance regarding this clinically important issue?

Item Type:Articles (Letter)
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Petrie, Professor John
Authors: Petrie, J.R.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences
Journal Name:New England Journal of Medicine
Publisher:Massachusetts Medical Society
ISSN:0028-4793
ISSN (Online):1533-4406
Published Online:01 January 2009

University Staff: Request a correction | Enlighten Editors: Update this record